THE HDx THERAPY ENABLED BY THERANOVA

The HDx therapy (expanded HD) is the next evolution in hemodialysis, as it effectively targets the removal of large middle molecules. Indeed, many of them are linked to the development of inflammation, cardiovascular disease, and other co-morbidities in dialysis patients. Not only can HDx therapy provide HDF performance and beyond in the removal of conventional middle and large middle molecules, it does so using regular HD workflow and infrastructure.

The HDx therapy is enabled by the Theranova® dialyzer series, featuring an innovative membrane design that combines a higher permeability than regular high-flux dialyzers with effective selectivity for large proteins.

HDF PERFORMANCE AND BEYOND, AS SIMPLE AS HD

- Markedly greater clearances and intradialytic reduction ratios for middle molecules than regular HD – at ordinary blood flow rates
- Equivalent removal of small and conventional middle molecules to high-volume HDF – Greater removal possible for large middle molecules
- Controlled albumin removal to between 1 and 4 grams per session
- Compatible with any HD monitor and with standard dialysis

WITH BAXTER’S LATEST DIALYZER INNOVATION, COMING CLOSER TO THE NATURAL KIDNEY

- High permeability to large middle molecules
- Effective selectivity by size exclusion
- Augmented internal filtration
- Similar retention of endotoxins as other dialysis membranes of the same material

* Do not use Theranova dialyzers in HDF or HF mode
**Theranova Specifications**

**MATERIALS**

<table>
<thead>
<tr>
<th>Membrane</th>
<th>THERANOVA 400</th>
<th>THERANOVA 500</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potting</td>
<td>Polyurethane (PUR)</td>
<td></td>
</tr>
<tr>
<td>Housing</td>
<td>Polyvinylpyrrolidone blend</td>
<td></td>
</tr>
<tr>
<td>Gaskets</td>
<td>Silicone rubber (SIR)</td>
<td></td>
</tr>
<tr>
<td>Protection caps</td>
<td>Polypropylene (PP)</td>
<td></td>
</tr>
<tr>
<td>Sterilization</td>
<td>Steam (inside-out)</td>
<td></td>
</tr>
<tr>
<td>Sterile barrier</td>
<td>Tyvek</td>
<td></td>
</tr>
</tbody>
</table>

**SPECIFICATIONS**

<table>
<thead>
<tr>
<th>UF-Coefficient (mL/(h<em>mmHg))</em></th>
<th>THERANOVA 400</th>
<th>THERANOVA 500</th>
</tr>
</thead>
<tbody>
<tr>
<td>KoA urea*</td>
<td>1482</td>
<td>1630</td>
</tr>
<tr>
<td>Blood Compartment volume (mL)</td>
<td>91</td>
<td>105</td>
</tr>
<tr>
<td>Minimum recommended priming volume (mL)</td>
<td>300</td>
<td></td>
</tr>
<tr>
<td>Maximum TMP (mmHg)</td>
<td>600</td>
<td></td>
</tr>
<tr>
<td>Recommended Qo (mL/min)</td>
<td>200-600</td>
<td>250-600</td>
</tr>
<tr>
<td>Storage conditions</td>
<td>&lt;30°C (or &lt;86°F)</td>
<td></td>
</tr>
<tr>
<td>Units per box</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Gross/net weight (g)</td>
<td>229/170</td>
<td>246/190</td>
</tr>
</tbody>
</table>

**MEMBRANE**

| Effective Membrane Area (m²) | 1.7 | 2.0 |
| Fiber inner diameter (µm) | 180 | |
| Fiber wall thickness (µm) | 35 | |

**SIEVING COEFFICIENTS**

- Vitamin B12 (1.4 kDa): 1.0
- Inulin (5.2 kDa): 1.0
- β2-microglobulin (11.8 kDa): 1.0
- Myoglobin (17 kDa): 0.9
- Albumin (66.4 kDa): 0.008

* According to EN 1283/ISO 8637:
  - UF-Coefficient: measured with bovine blood, Hct 32%, Pct 60g/L, 37°C
  - KoA urea: calculated at Qo=300 mL/min, Qd=500mL/min, UF=0 mL/min
  - Sieving coefficients: measured with human plasma, Qo=300 mL/min, UF=60 mL/min
  - Clearances In-Vitro: measured at UF=0 mL/min, ±10% (±20% Cyt. C, ±30% Myo.)

For further information visit hdxtheranova.com:

Baxter, MCO and Theranova are trademarks of Baxter International Inc. or its subsidiaries.

For safe and proper use of the device, please refer to the Instructions for Use


MANUFACTURER
Gambro Dialysatoren GmbH
Holger-Crafoord-Strasse 26
72379 Hechingen
Germany

Baxter Healthcare Corporation
One Baxter Parkway
Deerfield, IL 60015
USA
1-800-422-9837